Your browser is no longer supported. Please, upgrade your browser.
IMUX Immunic, Inc. daily Stock Chart
Immunic, Inc.
Index- P/E- EPS (ttm)-34.26 Insider Own0.30% Shs Outstand7.78M Perf Week-6.48%
Market Cap102.23M Forward P/E- EPS next Y-2.72 Insider Trans- Shs Float- Perf Month37.74%
Income-36.60M PEG- EPS next Q-0.68 Inst Own1.60% Short Float- Perf Quarter-8.43%
Sales- P/S- EPS this Y25.10% Inst Trans-12.02% Short Ratio0.77 Perf Half Y48.31%
Book/sh8.28 P/B1.59 EPS next Y- ROA-182.30% Target Price45.00 Perf Year-95.89%
Cash/sh1.23 P/C10.65 EPS next 5Y15.50% ROE-235.30% 52W Range6.04 - 390.00 Perf YTD76.33%
Dividend- P/FCF- EPS past 5Y12.00% ROI- 52W High-96.63% Beta3.68
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low117.55% ATR1.95
Employees10 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)54.82 Volatility13.88% 18.40%
OptionableYes Debt/Eq0.00 EPS Q/Q36.10% Profit Margin- Rel Volume0.53 Prev Close14.50
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume181.51K Price13.14
Recom1.50 SMA207.22% SMA5019.52% SMA20016.17% Volume96,491 Change-9.38%
Jul-11-19Initiated Chardan Capital Markets Buy $40
Jul-16-19 06:30AM  Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer PR Newswire -6.09%
Jun-24-19 06:30AM  Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston PR Newswire +90.86%
Jun-21-19 08:30AM  Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update PR Newswire -5.01%
Jun-04-19 06:30AM  Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2 Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway PR Newswire +10.18%
May-30-19 06:30AM  Immunic, Inc. to Participate in Investor and Scientific Conferences in June PR Newswire
May-09-19 06:30AM  Immunic, Inc. to Participate in Upcoming May Conferences PR Newswire
Apr-29-19 06:30AM  Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer PR Newswire
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.